- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00757211
Study of Genes and Environment in Patients With Breast Cancer in the East Anglia Region of the United Kingdom
A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Breast Cancer in East Anglia
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This study is looking at genetic susceptibility to cancer and interactions between genes and the environment in patients with breast cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- To obtain epidemiological information and biological material on a population-based series of breast cancer cases.
- To establish whether polymorphisms in putative cancer predisposition genes are associated with an increased risk of breast cancer by comparing the frequency of alterations in breast cancer patients with the corresponding frequency in controls.
- To define the proportion of breast cancer incidence attributable to mutations in such genes.
- To examine the interactions between genetic and nongenetic risk factors.
- To evaluate the relationship between pathological and clinical characteristics of breast cancers and germline genotype.
OUTLINE: This is a multicenter study.
Patients complete an epidemiological questionnaire that covers standard known breast cancer risk factors including reproductive history, oral contraceptive use, hormone replacement therapy use, family history, and alcohol consumption. The questionnaire will also request identifying information on the patient's first-degree relatives.
Blood samples are collected from patients. DNA is extracted from these blood samples, from samples collected from cancer-free control participants in MREC-SEARCH-CONTROL, and from additional controls through the European Prospective Investigation of Cancer (EPIC) study (a population-based study of diet and health based in Norfolk, East Anglia). DNA samples are analyzed for polymorphisms of low penetrance cancer susceptibility genes.
In addition to the breast cancer patients recruited for this study, patients with malignant melanoma and lymphoma, colorectal, ovarian, prostate, colorectal, bladder, kidney, pancreatic, and esophageal cancer, and brain tumors are recruited for the following related clinical trials: MREC-SEARCH-COLORECTAL, MREC-SEARCH-OVARIAN, MREC-SEARCH-PROSTATE, MREC-SEARCH-ENDOMETRIAL, and MREC-SEARCH-CANCER.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
England
-
Cambridge, England, United Kingdom, CB1 8RN
- Recruiting
- University of Cambridge Cancer Research UK
-
Contact:
- Contact Person
- Phone Number: 44-122-374-0166
- Email: paul.pharoah@srl.cam.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
- Diagnosis of breast cancer within the past 5 years
- Identified through the East Anglian Cancer Registry in the East Anglia region of the United Kingdom
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- Identified by the patient's general practitioner as fit to contact for this study
- No serious mental illness or retardation
PRIOR CONCURRENT THERAPY:
- Not specified
Study Plan
How is the study designed?
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Examination of the interactions between genetic and nongenetic risk factors
|
|
Acquisition of epidemiological information and biological material
|
|
Investigation of whether polymorphisms in putative cancer predisposition genes are associated with an increased risk of breast cancer
|
|
Proportion of breast cancer incidence attributable to mutations in such genes
|
|
Evaluation of the relationship between pathological and clinical characteristics of breast cancers and germline genotype
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Paul Pharoah, MD, Cancer Research UK
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000598878
- MREC-07/MRE05/17
- MREC-SEARCH-BREAST
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.